Background. A proinflammatory environment characterized by the continuous activation of the innate immune system is thought to contribute to the markedly elevated mortality in haemodialysis (HD) patients with end-stage renal disease (ESRD). The presence of circulating cell-free DNA (cfDNA) has been demonstrated as biomarker in many pathologies. Methods. We evaluated the occurrence of cfDNA in HD patients and its functional relevance for innate immunity and inflammation.
Introduction
End-stage renal disease (ESRD) patients under haemodialysis (HD) are characterized by a chronic inflammatory state that includes aberrant and chronic production of inflammatory cytokines such as interleukin (IL)-6 [1] [2] [3] . This proinflammatory environment occurring in ESRD patients has been implicated in HD comorbidity [4] . However, the basis for the constitutive activation of IL-6 production is unclear. It has been suggested that the systemic presence of uraemic proteins and the dialysis procedure itself may promote immune cell activation and hence inflammation [5] . It has long been recognized that innate immune cells are dysregulated during the course of ESRD [6, 7] .
Over the years, it has been increasingly documented that cell-free DNA (cfDNA) is present in blood under various healthy and pathological conditions [8] . Hence, cfDNA is regularly detected in plasma or serum samples of patients suffering from cancer, lupus erythematosus or in individuals after exhaustive exercise [8] [9] [10] . cfDNA has been found in many cases, in which apoptosis or necrosis was involved suggesting that such events are the main source for its presence [8, 10] . Recently, it was described that cfDNA is released during the HD procedure [10] [11] [12] . However, the underlying reasons for the release of cfDNA and the functional effects of uraemic cfDNA have not been investigated.
Materials and methods

Study subjects
Patients with ESRD undergoing maintenance HD for a minimum of 3 months were recruited for the study. Patients were in a stable condition and free from intercurrent illness and infection for at least 3 months. All patients were dialysed on standard bicarbonate basis for 4-5 h three times weekly using biocompatible polysulphone HD membranes (Fresenius). A group of healthy subjects with normal kidney function were used as control group. All individuals gave written informed consent prior to their inclusion in the study, which was performed in accordance with the ethical standards laid down Declaration of Helsinki. Ethical approval has been provided by the locally ethics committee of the General Hospital of Vienna (EK 407/2007).
Plasma isolation from blood
Blood samples were drawn in EDTA tubes from a total of 23 HD patients and 14 healthy controls. The blood samples of the HD patients were drawn at the end of the dialysis session. Blood was immediately placed on ice and centrifuged at 1000 RCF for 15 min at 4°C to obtain plasma.
Isolation and quantitation of cfDNA from blood
Within the first 2 h of obtaining plasma samples, DNA from individual samples was either isolated from 800 lL of plasma using a DNA isolation mini kit (Qiamp Blood Mini Kit; Qiagen) for quantitation of cfDNA or from 10 mL plasma samples using the Qiamp Blood Maxi Kit (Qiagen) for functional assays according to the manufacturer's protocol. The DNA was eluted in 50 lL (Mini Kit) or 500 lL (Maxi Kit) of elution buffer. cfDNA concentration was measured using a Nanodrop measurement device (Thermo Scientific).
Agarose gel electrophoresis
To separate plasma DNA, agarose gel electrophoresis was performed. Gels were stained with Vistra Green (Amersham Biosciences). As positive control for apoptotic DNA, we loaded genomic DNA that was isolated from peripheral blood mononuclear cells (PBMCs) treated with 5 lM staurosporine (STS).
Monocyte stimulation
Monocytes were isolated as described [13] . Freshly isolated monocytes were seeded in 48-well plates adjusted to a final volume of 2.5 3 10 5 cells/ 0.5 mL. Monocytes were stimulated with 250 ng/mL cfDNA or with 10, 100 and 200 lL of plasma from HD patients or healthy controls. In some experiments, we treated 200 lL HD plasma with 8 U DNase I (New England Biolabs) for 24 h. Cell-free supernatants were collected after 24 h. IL-6, tumour necrosis factor (TNF)-a and IL-10 in the supernatants were measured by Luminex (R&D Systems).
Statistics
Results are expressed as means AE SEM. Student's t-test was used to detect statistical significance. For all statistical analyses, significant differences are marked in the graphics with *P < 0.05 or ***P < 0.001.
Results
cfDNA is enhanced in plasma of HD patients
We found that plasma of ESRD patients, after the dialysis session (HD), contained a significantly elevated amount of cfDNA compared to healthy individuals (mean of 0.98 ng/ lL plasma versus 0.43 ng/lL, respectively) ( Figure 1A ). To further characterize the plasma, we performed agarose gel electrophoresis. Interestingly, we observed that the cfDNA of HD patients had a pattern-like appearance that is typical for apoptosis ( Figure 1B) . In contrast, the plasma cfDNA of healthy controls did not show this apoptotic pattern ( Figure 1B) . These results indicate that the amount of cfDNA is augmented in plasma of HD patients potentially because of apoptosis of PBMCs induced by the dialysis procedure.
cfDNA selectively stimulates IL-6 production in human monocytes Next, we wanted to characterize the functional properties of cfDNA. To this end, we purified cfDNA from the plasma of HD patients and healthy controls and tested if cfDNA is able to activate primary human monocytes, one of the cardinal innate immune cells in the blood. We observed that cfDNA isolated from HD patients induced the production of the proinflammatory cytokine IL-6 in monocytes (Figure 2A ). Neither TNF-a nor IL-10 was induced by cfDNA indicating that cfDNA selectively induces IL-6 expression in monocytes (Figure 2A) . Interestingly, cfDNA from healthy controls likewise stimulated IL-6 production in a comparable fashion to cfDNA from HD patients (Figure 2A) . These results provide the first evidence that cfDNA, irrespective of the origin, promotes the production of IL-6 in human monocytes.
Plasma from HD patients promotes IL-6 production in human monocytes
Although cfDNA from HD patients and healthy controls was similarly potent to induce IL-6, we speculated that HD plasma might be able to more strongly activate monocytes as cfDNA is present in higher amounts in the plasma of HD patients. As shown in (Figure 2B ), pure plasma of HD patients dose dependently induced the production of IL-6 in human monocytes, whereas plasma from healthy controls did not stimulate IL-6. To more directly address whether the presence of cfDNA in the plasma of HD patients induces IL-6 production, we treated HD plasma with DNase I to degrade DNA. We observed that the DNase I-treated HD plasma showed a reduced capacity to induce IL-6 in human monocytes. These results suggest that the cfDNA present in plasma of HD patients is a driver of IL-6 production.
Discussion
Large clinical studies have shown that the mortality rate of individuals with ESRD undergoing HD is markedly elevated. This has been attributed among other things to the constitutive occurrence of inflammation in many patients, and hence, inflammatory markers such as C-reactive protein or IL-6 are powerful predictors of mortality in this patient group [14] [15] [16] . The inflammatory environment in HD patients has been attributed to the incomplete removal of uraemic toxins that promote inflammatory reactions but also to the HD procedure itself [5] . Dialysis membranes and uraemic plasma can promote apoptosis of human Fig. 1 . cfDNA in plasma of HD patients and healthy controls. Plasma was obtained from 13 HD patients and 9 healthy controls. (A) DNA was isolated and concentrations were measured as described in the Materials and methods section. cfDNA concentrations in plasma of HD patients and controls (ctrl). *P < 0.05. (B) Agarose gel electrophoresis was performed to characterize DNA samples. Lane 1, molecular size marker (the size of the bands is shown in bp); Lane 2: apoptotic DNA; Lanes 3-6: cfDNA samples of HD patients; Lanes 7-10: cfDNA samples of healthy controls. polymorphonuclear neutrophils and mononuclear cells directly as well as through their interactions with monocytes [17] [18] [19] [20] [21] [22] . It is thought that these apoptotic leucocytes then activate the innate immune system to contribute to the proinflammatory environment in ESRD patients undergoing HD.
cfDNA has been found in many pathologies, in which apoptosis or necrosis is involved suggesting that such events are a source for its presence [8] . cfDNA has been evaluated primarily as biomarker so far, whereas potential functional effects of cfDNA have not been investigated [8] . Also in ESRD patients on HD, the presence of cfDNA has been described [10] [11] [12] . We speculated that cfDNA present in HD patients may activate the innate immune system to promote proinflammatory events. Indeed, we observed that cfDNA isolated from HD patients induced the production of IL-6 from human monocytes. This effect was selective as cfDNA did not induce TNF-a or IL-10. Moreover, it is noteworthy that cfDNA from healthy individuals similarly induced IL-6 indicating that the main difference between HD patients and healthy controls regarding cfDNA is the absolute amount of cfDNA, which is elevated in patients with HD. Conversely, plasma from HD patients but not from healthy individuals was able to induce the expression of IL-6 from monocytes. Moreover, DNase I-treated HD plasma showed a severely reduced ability to induce IL-6. These results suggest that cfDNA in the HD plasma contributes to the constitutive proinflammatory events in these patients.
In conclusion, we found in the current study that cfDNA released from blood cells by ongoing apoptosis is abundantly present in the plasma of HD patients. Importantly, we have shown for the first time that cfDNA is able to selectively induce the production of the proinflammatory cytokine IL-6 in human monocytes. We further established that the plasma of HD patients, but not of healthy controls, mimicked the capacity of cfDNA to induce IL-6 in human monocytes indicating that this process may contribute to the proinflammatory environment observed in HD patients.
